ResearcherLMU KlinikumActive in the last 2 years

Ignazio Piseddu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8331-9778; OpenAlex author ID A5004890730. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 9

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

STING Ablation in T Cells Is Required for the Efficacy of STING Agonists in CAR-T Cell Immunotherapy of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.01.031 ↗
TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status. Co-author DOI 10.3390/cancers14215240 ↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Julia V. Mayerle · 2 shared papers, 2022–2026 · strength 0.34
- Paper STING Ablation in T Cells Is Required for the Efficacy of STING Agonists in CAR-T Cell Immunotherapy of Pancreatic Canc… DOI 10.1053/j.gastro.2026.01.031 ↗
- Paper TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation… DOI 10.3390/cancers14215240 ↗
Ivonne Regel · 1 shared paper, 2026 · strength 0.21
- Paper STING Ablation in T Cells Is Required for the Efficacy of STING Agonists in CAR-T Cell Immunotherapy of Pancreatic Canc… DOI 10.1053/j.gastro.2026.01.031 ↗
Veit Hornung · 1 shared paper, 2026 · strength 0.21
- Paper STING Ablation in T Cells Is Required for the Efficacy of STING Agonists in CAR-T Cell Immunotherapy of Pancreatic Canc… DOI 10.1053/j.gastro.2026.01.031 ↗
Sebastian Kobold · 1 shared paper, 2026 · strength 0.21
- Paper STING Ablation in T Cells Is Required for the Efficacy of STING Agonists in CAR-T Cell Immunotherapy of Pancreatic Canc… DOI 10.1053/j.gastro.2026.01.031 ↗
Anne Marie Senz · 1 shared paper, 2026 · strength 0.21
- Paper STING Ablation in T Cells Is Required for the Efficacy of STING Agonists in CAR-T Cell Immunotherapy of Pancreatic Canc… DOI 10.1053/j.gastro.2026.01.031 ↗
Simon Sirtl · 1 shared paper, 2022 · strength 0.13
- Paper TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation… DOI 10.3390/cancers14215240 ↗
Enrico Narciso De Toni · 1 shared paper, 2022 · strength 0.13
- Paper TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation… DOI 10.3390/cancers14215240 ↗
Najib Ben Khaled · 1 shared paper, 2022 · strength 0.13
- Paper TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation… DOI 10.3390/cancers14215240 ↗
Ujjwal Mukund Mahajan · 1 shared paper, 2022 · strength 0.13
- Paper TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation… DOI 10.3390/cancers14215240 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.